Merck had a Q3 conference call on 10/27/15 and indicated, regarding their CETP inhibitor anacetrapib REVEAL Phase 3 trial:

"Six months ago, we reported that the REVEAL Steering Committee wished to adjust the primary endpoint to substitute ischemic stroke for revascularization, reflecting evidence from IMPROVE-IT, where a benefit was observed on the incidence of this more easily adjudicated endpoint. After discussions with regulatory agencies, however, this change was deemed inadvisable. Hence, as of today, the Steering Committee plans to continue along the path originally outlined in the study protocol. There will be an interim analysis before the end of the year, and in light of the results obtained with evacetrapib, it is anticipated that a futility component will be included in this analysis."

8 weeks left in 2015. The jury is still out on whether another CETP Phase 3 trial will be ended early similar to what happened last month with Eli Lilly and evacetrapib/ACCELERATE trial.